Categories: Clinical Research

Eisai to Give Oral Presentation on Results of Phase III Head-to-Head Clinical Study of Lemborexant in Insomnia Disorder

At 43rd Annual Meeting of The Japan Society of Sleep Research

At “Drug Discovery Research For Sleep Medicine” Symposium

Tokyo, July 04, 2018: Eisai Co., Ltd. today announced that the latest data from a Phase III clinical study (SUNRISE 1) on its investigational sleep-wake regulation agent lemborexant (development code: E2006), will be presented in an oral presentation at the 43rd Annual Meeting of the Japan Society of Sleep Research being held from July 11 to 13 in Sapporo, Japan. This presentation will be given at the symposium “Drug Discovery Research for Sleep Medicine”.

The symposium will report on the latest data on lemborexant from non-clinical research and clinical studies relating to insomnia, including the results of SUNRISE 1. In addition to SUNRISE 1 in which the primary and key secondary objectives were achieved, non-clinical research data from the course of discovery of lemborexant, including medicinal chemistry and pharmacology, will also be highlighted at the symposium.

With a robust polysomnography (PSG) data set, SUNRISE 1 was a Phase III clinical study of the efficacy and safety of lemborexant versus placebo and an active comparator (zolpidem tartrate extended release, “zolpidem ER”) in approximately 1,000 patients 55 years and older with insomnia disorder. The study evaluated change from baseline for both sleep onset (primary objective) and sleep maintenance variables (secondary objectives), including the time spent awake in the second half of the night, which is a common complaint, especially in older patients. The study used objective PSG to determine if 5 mg and 10 mg reduced time to sleep onset and prolonged sleep maintenance compared to zolpidem ER 6.25 mg and to placebo. In this study, lemborexant had rates of discontinuation due to adverse events (AEs) comparable to placebo, with the most common AEs in the lemborexant arms being headache and somnolence.

Discovered by Eisai, lemborexant is being jointly developed by Eisai and Purdue Pharma L.P.

Lemborexant appears to impact an underlying reason for a patient’s inability to sleep and wake well. Lemborexant acts on the orexin neurotransmitter system and is believed to regulate sleep and wake by dampening wakefulness without impeding the ability to awaken to external stimuli.

Through research and development on lemborexant, Eisai and Purdue are striving to bring to patients with sleep-wake disorders a new treatment option for sleep-wake regulation that improves their ability to fall asleep and stay asleep, without impairing them the next morning.

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau

Recent Posts

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

10 hours ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

1 day ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

4 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

5 days ago

Hon’ble Prime Minister Shri Narendra Modi Inaugurates LyfiusPharma’s Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…

6 days ago